全文获取类型
收费全文 | 1321篇 |
免费 | 92篇 |
国内免费 | 28篇 |
专业分类
儿科学 | 127篇 |
妇产科学 | 14篇 |
基础医学 | 116篇 |
口腔科学 | 51篇 |
临床医学 | 147篇 |
内科学 | 259篇 |
皮肤病学 | 13篇 |
神经病学 | 36篇 |
特种医学 | 258篇 |
外科学 | 159篇 |
综合类 | 35篇 |
预防医学 | 97篇 |
眼科学 | 29篇 |
药学 | 58篇 |
肿瘤学 | 42篇 |
出版年
2023年 | 6篇 |
2022年 | 4篇 |
2021年 | 21篇 |
2020年 | 10篇 |
2019年 | 15篇 |
2018年 | 23篇 |
2017年 | 13篇 |
2016年 | 13篇 |
2015年 | 23篇 |
2014年 | 30篇 |
2013年 | 22篇 |
2012年 | 19篇 |
2011年 | 25篇 |
2010年 | 50篇 |
2009年 | 29篇 |
2008年 | 33篇 |
2007年 | 60篇 |
2006年 | 51篇 |
2005年 | 39篇 |
2004年 | 47篇 |
2003年 | 51篇 |
2002年 | 36篇 |
2001年 | 33篇 |
2000年 | 31篇 |
1999年 | 35篇 |
1998年 | 67篇 |
1997年 | 79篇 |
1996年 | 81篇 |
1995年 | 50篇 |
1994年 | 44篇 |
1993年 | 45篇 |
1992年 | 25篇 |
1991年 | 19篇 |
1990年 | 23篇 |
1989年 | 47篇 |
1988年 | 41篇 |
1987年 | 31篇 |
1986年 | 30篇 |
1985年 | 32篇 |
1984年 | 10篇 |
1983年 | 10篇 |
1982年 | 13篇 |
1981年 | 10篇 |
1980年 | 13篇 |
1979年 | 3篇 |
1978年 | 4篇 |
1977年 | 14篇 |
1976年 | 10篇 |
1975年 | 7篇 |
1946年 | 2篇 |
排序方式: 共有1441条查询结果,搜索用时 15 毫秒
51.
Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia 总被引:4,自引:0,他引:4
Foon KA; Schroff RW; Bunn PA; Mayer D; Abrams PG; Fer M; Ochs J; Bottino GC; Sherwin SA; Carlo DJ 《Blood》1984,64(5):1085-1093
A phase I clinical trial was initiated to treat patients with stage IV B-derived chronic lymphocytic leukemia (CLL) with the IgG2a murine monoclonal antibody T101. This antibody binds to a 65,000-mol wt (T65) antigen found on normal T lymphocytes, malignant T lymphocytes, and B- derived CLL cells. All of the patients had a histologically confirmed diagnosis of advanced B-derived CLL and were refractory to standard therapy, and more than 50% of their leukemia cells reacted with the T101 antibody in vitro. The patients received T101 antibody two times per week, over two to 50 hours by intravenous administration in 100 mL of normal saline containing 5% human albumin. Twelve patients were treated with a fixed dosage of 1, 10, 50, or 100 mg, and one patient was treated with 140 mg of antibody. It was demonstrated that patients given two-hour infusions of 50 mg developed pulmonary toxicity, with shortness of breath and chest tightness. This toxicity was eliminated when infusions of 50 or 100 mg of T101 were prolonged to 50 hours. All dose levels caused a rapid but transient decrease in circulating leukemia cell counts. In vivo binding to circulating and bone marrow leukemia cells was demonstrated at all dose levels with increased binding at higher dosages. Antimurine antibody responses were not demonstrated in any patients at any time during treatment. Circulating free murine antibody was demonstrated in the serum of only the two patients treated with 100 mg of antibody as a 50-hour infusion and the patient treated with 140 mg of antibody over 30 hours. Antigenic modulation was demonstrated in patients treated at all dose levels but was particularly apparent in patients treated with prolonged infusions of 50 and 100 mg of antibody. We were also able to demonstrate antigenic modulation in lymph node cells, which strongly suggests in vivo labeling of these cells. Overall, T101 antibody alone appears to have a very limited therapeutic value for patients with CLL. The observations of in vivo labeling of tumor cells, antigenic modulation, antibody pharmacokinetics, toxicity, and antimurine antibody formation may be used in the future for more effective therapy when drugs or toxins are conjugated to the antibody. 相似文献
52.
53.
Oren Ledder Wolfram Haller Richard TL Couper Peter Lewindon Mark Oliver 《Journal of gastroenterology and hepatology》2014,29(12):1954-1962
This paper, the second in the series, will build on the first and explore the importance of liver and pancreatic manifestations of cystic fibrosis (CF) and the effect on morbidity and mortality of this multifaceted genetic condition. It will also further develop the critical role of the gastroenterologist as part of the multidisciplinary group of clinicians and allied health staff in the effective management of patients with CF. 相似文献
54.
55.
56.
Jones CD Loehr L Franceschini N Rosamond WD Chang PP Shahar E Couper DJ Rose KM 《Hypertension》2012,59(5):913-918
Heart failure causes significant morbidity and mortality. Distinguishing risk factors for incident heart failure can help identify at-risk individuals. Orthostatic hypotension may be a risk factor for incident heart failure; however, this association has not been fully explored, especially in nonwhite populations. The Atherosclerosis Risk in Communities Study included 12363 adults free of prevalent heart failure with baseline orthostatic measurements. Orthostatic hypotension was defined as a decrease of systolic blood pressure ≥20 mmHg or diastolic blood pressure ≥10 mmHg with position change from supine to standing. Incident heart failure was identified from hospitalization or death certificate disease codes. Over 17.5 years of follow-up, orthostatic hypotension was associated with incident heart failure with multivariable adjustment (hazard ratio: 1.54 [95% CI: 1.30-1.82]). This association was similar across race and sex groups. A stronger association was identified in younger individuals ≤55 years old (hazard ratio: 1.90 [95% CI: 1.41-2.55]) than in older individuals >55 years old (hazard ratio: 1.37 [95% CI: 1.12-1.69]; interaction P=0.034). The association between orthostatic hypotension and incident heart failure persisted with exclusion of those with diabetes mellitus, coronary heart disease, and those on antihypertensives or psychiatric or Parkinson disease medications. However, exclusion of those with hypertension somewhat attenuated the association (hazard ratio: 1.34 [95% CI: 1.00-1.80]). We identified orthostatic hypotension as a predictor of incident heart failure among middle-aged individuals, particularly those 45 to 55 years of age. This association may be partially mediated through hypertension. Orthostatic measures may enhance risk stratification for future heart failure development. 相似文献
57.
EG Burden RW Walker DJ Ferguson AMF Goubran JR Howell JB John F Khan JS McGrath JP Evans 《Annals of the Royal College of Surgeons of England》2021,103(3):173
IntroductionWith the emergence of the COVID-19 pandemic, all elective surgery was temporarily suspended in the UK, allowing for diversion of resource to manage the anticipated surge of critically unwell patients. Continuing to deliver time-critical surgical care is important to avoid excess morbidity and mortality from pathologies unrelated to COVID-19. We describe the implementation and short-term surgical outcomes from a system to deliver time-critical elective surgical care to patients during the COVID-19 pandemic.Materials and methodsA protocol for the prioritisation and safe delivery of time-critical surgery at a COVID-19 ‘clean’ site was implemented at the Nuffield Health Exeter Hospital, an independent sector hospital in the southwest of England. Outcomes to 30 days postoperatively were recorded, including unplanned admissions after daycase surgery, readmissions and complications, as well as the incidence of perioperative COVID-19 infection in patients and staff.ResultsA total of 128 surgical procedures were performed during a 31-day period by a range of specialties including breast, plastics, urology, gynaecology, vascular and cardiology. There was one unplanned admission and and two readmissions. Six complications were identified, and all were Clavien-Dindo grade 1 or 2. All 128 patients had preoperative COVID-19 swabs, one of which was positive and the patient had their surgery delayed. Ten patients were tested for COVID-19 postoperatively, with none testing positive.ConclusionThis study has demonstrated the implementation of a safe system for delivery of time-critical elective surgical care at a COVID-19 clean site. Other healthcare providers may benefit from implementation of similar methodology as hospitals plan to restart elective surgery. 相似文献
58.
Ki Wook Kim Digby W. Allen Thomas Briese Jennifer J. Couper Simon C. Barry Peter G. Colman Andrew M. Cotterill Elizabeth A. Davis Lynne C. Giles Leonard C. Harrison Mark Harris Aveni Haynes Jessica L. Horton Sonia R. Isaacs Komal Jain Walter I. Lipkin Kelly McGorm Grant Morahan Claire Morbey Ignatius C. N. Pang Anthony T. Papenfuss Megan A. S. Penno Richard O. Sinnott Georgia Soldatos Rebecca L. Thomson Peter Vuillermin John M. Wentworth Marc R. Wilkins William D. Rawlinson Maria E. Craig 《Pediatric diabetes》2020,21(2):271-279
59.
60.
Naiara G. Bediaga Alexandra L. Garnham Gaetano Naselli Esther Bandala-Sanchez Natalie L. Stone Joanna Cobb Jessica E. Harbison John M. Wentworth Annette-G. Ziegler Jennifer J. Couper Gordon K. Smyth Leonard C. Harrison 《Diabetes》2022,71(3):566
Type 1 diabetes in children is heralded by a preclinical phase defined by circulating autoantibodies to pancreatic islet antigens. How islet autoimmunity is initiated and then progresses to clinical diabetes remains poorly understood. Only one study has reported gene expression in specific immune cells of children at risk associated with progression to islet autoimmunity. We analyzed gene expression with RNA sequencing in CD4+ and CD8+ T cells, natural killer (NK) cells, and B cells, and chromatin accessibility by assay for transposase-accessible chromatin sequencing (ATAC-seq) in CD4+ T cells, in five genetically at risk children with islet autoantibodies who progressed to diabetes over a median of 3 years (“progressors”) compared with five children matched for sex, age, and HLA-DR who had not progressed (“nonprogressors”). In progressors, differentially expressed genes (DEGs) were largely confined to CD4+ T cells and enriched for cytotoxicity-related genes/pathways. Several top-ranked DEGs were validated in a semi-independent cohort of 13 progressors and 11 nonprogressors. Flow cytometry confirmed that progression was associated with expansion of CD4+ cells with a cytotoxic phenotype. By ATAC-seq, progression was associated with reconfiguration of regulatory chromatin regions in CD4+ cells, some linked to differentially expressed cytotoxicity-related genes. Our findings suggest that cytotoxic CD4+ T cells play a role in promoting progression to type 1 diabetes. 相似文献